Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
43 studies found for:    ovarian,cancer,detection | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Fermented Wheat Germ Extract in Women With Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Fermented Wheat Germ Extract (FWGE);   Drug: Placebo;   Procedure: Planned Surgery;   Other: Quality of Life (QoL) Surveys: FACT-O
22 Recruiting Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making
Conditions: Ovarian Cancer;   PROM;   Quality of Life
Intervention:
23 Recruiting Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: PDS;   Drug: 6 cycles of standard chemotherapy;   Drug: 3 cycles of standard NACT;   Procedure: IDS;   Drug: 3 cycles of standard chemotherapy
24 Not yet recruiting Prospective Validation and Comparison of Different Ultrasound Methods for Discrimination Between Benign and Malignant Ovarian/Tubal Masses Prior to Surgery
Condition: Patients With Adnexal Mass Prior to Surgery
Intervention: Other: Standardized transvaginal ultrasound examination
25 Not yet recruiting Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer
Condition: Ovarian Neoplasms
Intervention:
26 Recruiting Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
Conditions: Adnexal Mass;   Borderline Ovarian Epithelial Tumor;   Ovarian Clear Cell Tumor;   Ovarian Endometrioid Tumor;   Ovarian Neoplasm;   Ovarian Serous Tumor;   Recurrent Ovarian Carcinoma
Interventions: Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Valproic Acid
27 Not yet recruiting PET Imaging of Ovarian Carcinoma With 18F-FSPG
Conditions: Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Radiation: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG);   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis
28 Recruiting Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma
Conditions: Ovarian Epithelial Cancer;   Carcinoma in Situ;   Ovarian Cancer
Intervention: Procedure: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
29 Not yet recruiting DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
Conditions: Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Intervention:
30 Recruiting FSH-R : Diagnostic Application for Localized Tumors in Cancerology
Condition: Cancer
Intervention: Procedure: blood sample for FSHR analysis
31 Recruiting Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors
Conditions: Minimal Residual Disease;   Fertility Preservation
Intervention: Other: malignant cells
32 Recruiting Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients
Conditions: Hypopituitarism;   Hypogonadism;   Thyroid Dysfunction;   Bone Diseases, Metabolic
Intervention:
33 Recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
34 Not yet recruiting Value of MRI in the Characterization of Ovarian Masses Unable to Classify With Ultrasound Using the International Ovarian Tumor Analysis (IOTA) Simple Rules
Condition: Patients With a Sonographically Unclassifiable Adnexal Mass Using the IOTA Simple Rules
Intervention: Other: Diffusion/Perfusion-weighted Magnetic Resonance Imaging
35 Recruiting Development of Ovarian Tissue Autograft in Order to Restore Ovarian Function
Condition: Ovarian Function Insufficiency
Intervention: Procedure: Autograft of cryopreserved ovarian tissue
36 Not yet recruiting Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine
Condition: Endometrial Cancer
Intervention:
37 Recruiting Investigating Minimal Residual Disease in Autopreserved Ovarian Tissue in Cases of Neoplastic Pathology
Conditions: Neoplastic Pathology;   Autopreserved Ovarian Tissue
Intervention:
38 Recruiting Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)
Condition: Renal Cell Carcinoma
Intervention: Drug: EC17
39 Recruiting Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors
Condition: Cancer
Interventions: Other: blood samples;   Other: Urine samples
40 Not yet recruiting MED-C Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Conditions: Neoplasms;   Lung Neoplasms;   Colon Neoplasms;   Breast Neoplasms;   Pancreatic Neoplasms;   Prostate Neoplasms;   Kidney Neoplasms;   Liver Neoplasms;   Rectal Neoplasms;   Hematologic Neoplasms;   Multiple Myeloma;   Myelodysplastic Syndromes;   Ovarian Neoplasms;   Bladder Neoplasms;   Testicular Neoplasms;   Endometrial Neoplasms;   Brain Neoplasms;   Biliary Tract Neoplasms;   Head and Neck Neoplasms;   Uterine Cervical Neoplasms;   Skin Neoplasms;   Melanoma;   Gastric Neoplasms;   Anal Neoplasms;   Sarcoma
Intervention: Other: Provider determined

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-43) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.